Selected scientific papers
This section contains a selection of Dr. Breggin's scientific articles spanning 1964 to the present. They can be arranged chronologically in order to facilitate an overview of his work over the years.
 
 

DocumentsDate added

Order by : Name | Date | Hits [ Ascendant ]
file icon The FDA should test the safety of ECT machines 07/13/2010
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
 
Peter R. Breggin
 
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.
file icon Harms of Exposure to SSRIs In Utero (2008) 02/10/2010
"Exposure to SSRI Antidepressants In Utero Causes Birth Defects, Neonatal Withdrawal Symptoms, and Brain Damage." Ethical Human Psychology and Psychiatry, 10, 5-9, 2008.
file icon Guidelines for Counseling and Psychotherapy (2008) 02/10/2010
"Practicle Applications: 22 Guidelines for Counseling and Psychotherapy." Ethical Human Psychology and Psychiatry, 10, 43-57, 2008.
file icon ECT Damages the Brain: Disturbing News (2007) 10/24/2008
"ECT Damages the Brain: Disturbing News for Patients and Shock Doctors Alike." Ethical Human Psychology and Psychiatry, 9, 83-86, 2007.
file icon Paxil Special Report III: Drug Company Suppressed Data on Paxil (2006) 05/01/2006
"Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide", Ethical Human Psychology and Psychiatry, 8, 255-263, 2006.
file icon Paxil Special Report II: How GSK suppressed Paxil data (2006) 04/01/2006
"How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence", Ethical Human Psychology and Psychiatry, 8, 91-100, 2006.
file icon Paxil Special Report I: Court filing makes suppressed Paxil data public ('06) 03/01/2006
"Court Filing Makes Public My Previously Suppressed Analysis of Paxil's Effects." Ethical Human Psychology and Psychiatry, 8, 77-84, 2006.
file icon Politics, practice, and breaking news (2006) 02/01/2006
"Politics, Practice, and Breaking News." Ethical Human Psychology and Psychiatry, 8, 3-6, 2006.
file icon Recent regulatory changes in antidepressant labels: Implications for activation (2006) 01/01/2006
"Recent regulatory changes in antidepressant labels: Implications for activation (stimulation) in clinical practice." Primary Psychiatry, 13, 57-60, 2006.
file icon Recent U.S., Canadian and British regulatory agency actions concerning antidepressants (2005) 01/01/2005
"Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: A review and analysis." Ethical Human Psychology and Psychiatry, 7, 7-22, 2005. Simultaneously published in the International Journal of Risk and Safety in Medicine, 16, 247-259, 2005.
<< Start < Prev 1 2 3 4 5 6 7 8 Next > End >>
Results 11 - 20 of 76

 

WARNING!

Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families.